The present findings strengthen the rationale for Notch-tailored therapies in MM providing evidences that knocking down MM-derived JAGGED ligands may reduce MM tumor burden by decreasing the amount of IL-6 in the BM niche. The gene discussed is IL6; the disease is neoplasm.